- Home
- ACTG vs CLLS Comparison
ACTG vs CLLS Comparison
Compare ACTG & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACTG | CLLS |
|---|---|---|
| Founded | 1993 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.5M | 394.4M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACTG | CLLS |
|---|---|---|
| Price | $4.63 | $3.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 255.7K | 15.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,004,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.15 | $2.35 |
| 52 Week High | $5.27 | $5.48 |
Technical Indicators
Market Signals| Indicator | ACTG | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout ACTG Acacia Research Corporation (Acacia Tech)
Acacia Research Corp is focused on acquiring and operating businesses across the industrial, energy, and technology sectors where it believes it can leverage its expertise, capital base, and deep industry relationships to drive value. The company has four reportable business segments: Intellectual Property Operations, Industrial Operations, Energy Operations, and Manufacturing Operations. It derives revenue from the Intellectual Property Operations segment. Geographically, it operates in the Americas, Europe, the Middle East and Africa, China, India, and Asia-Pacific.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.